刊名:European Journal of Drug Metabolism and Pharmacokinetics
出版年:2017
出版时间:February 2017
年:2017
卷:42
期:1
页码:109-116
全文大小:
刊物主题:Pharmacology/Toxicology; Pharmacy; Human Physiology; Pharmaceutical Sciences/Technology; Medical Biochemistry;
出版者:Springer International Publishing
ISSN:2107-0180
卷排序:42
文摘
Background and ObjectiveSacubitril/valsartan (LCZ696) is a first-in-class angiotensin receptor neprilysin inhibitor (ARNI) and has been recently approved in several countries for the treatment of patients with heart failure and reduced ejection fraction. This was the first study conducted to characterise the pharmacokinetics of LCZ696 analytes (pro-drug sacubitril, active neprilysin inhibitor LBQ657 and valsartan) after single-dose administration of LCZ696 in healthy Chinese subjects.